MX9305082A - Sustancias proteinaceas biologicamente activas de oxido polialquilenico de bajo diol. - Google Patents

Sustancias proteinaceas biologicamente activas de oxido polialquilenico de bajo diol.

Info

Publication number
MX9305082A
MX9305082A MX9305082A MX9305082A MX9305082A MX 9305082 A MX9305082 A MX 9305082A MX 9305082 A MX9305082 A MX 9305082A MX 9305082 A MX9305082 A MX 9305082A MX 9305082 A MX9305082 A MX 9305082A
Authority
MX
Mexico
Prior art keywords
biologically active
proteinaceas
substances
polyalkylene oxide
low diol
Prior art date
Application number
MX9305082A
Other languages
English (en)
Inventor
Christopher P Phillips
Robert A Snow
David L Ladd
Denton W Hoyer
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of MX9305082A publication Critical patent/MX9305082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se divulgan composiciones farmacéuticas conteniendo óxido de diol polialqueno inferior, tal como glicol de polietileno, covalentemente ligado a una sustancia proteinasea biológicamente activa y proceso de elaboración de las composiciones. Además se divulga un método de tratamiento de procesos de epidemias asociadas con los efectos adversos sobre tejidos de aniones de superoxido, tales como inflamación y trauma, padecimientos de repercusión, situaciones isoquemicas.
MX9305082A 1992-08-27 1993-08-20 Sustancias proteinaceas biologicamente activas de oxido polialquilenico de bajo diol. MX9305082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93641692A 1992-08-27 1992-08-27

Publications (1)

Publication Number Publication Date
MX9305082A true MX9305082A (es) 1994-02-28

Family

ID=25468595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305082A MX9305082A (es) 1992-08-27 1993-08-20 Sustancias proteinaceas biologicamente activas de oxido polialquilenico de bajo diol.

Country Status (7)

Country Link
US (2) US5532150A (es)
EP (1) EP0584876A3 (es)
JP (1) JPH06172201A (es)
AU (1) AU675798B2 (es)
CA (1) CA2101361A1 (es)
HU (1) HUT66755A (es)
MX (1) MX9305082A (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
ES2174915T3 (es) * 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2206852A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
WO1996032130A1 (en) * 1995-04-10 1996-10-17 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5868868A (en) * 1995-06-19 1999-02-09 Alcon Laboratories, Inc. Peg-modified proteases and methods of use in contact lens cleaning
US5718895A (en) * 1995-11-16 1998-02-17 Alcon Laboratories, Inc. Enzymes with low isoelectric points for use in contact lens cleaning
WO1997024421A2 (en) * 1995-12-29 1997-07-10 The Procter & Gamble Company Detergent compositions comprising immobilized enzymes
JP3092530B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
US6321909B1 (en) * 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
EP0968291B1 (en) 1997-02-21 2004-01-28 Genentech, Inc. Antibody fragment-polymer conjugates
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU751880B2 (en) * 1997-06-25 2002-08-29 Novozymes A/S A modified polypeptide
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
WO1999049056A1 (en) 1998-03-26 1999-09-30 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
CA2379729A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
AU5928100A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
CZ2002212A3 (cs) 1999-07-22 2002-07-17 The Procter & Gamble Company Varianty subtilisinové proteasy mající aminokyselinové substituce v definovaných epitopových oblastech
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
BR0317742A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
EP1696947B1 (en) 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
DE102004059489C5 (de) 2004-12-10 2011-12-08 Clariant Produkte (Deutschland) Gmbh Verfahren zur Herstellung von reinen alpha-Alkoxy-omega-hydroxy-Polyalkylenglykolen
CN109112119B (zh) * 2018-08-28 2022-04-26 佛山科学技术学院 经化学修饰的鸭血sod制剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
EP0893439B1 (en) * 1989-04-19 2005-07-27 Enzon, Inc. A process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide
WO1993002701A1 (en) * 1991-08-05 1993-02-18 Sterling Winthrop Inc. Buffered formulation of peg-sod
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances

Also Published As

Publication number Publication date
EP0584876A2 (en) 1994-03-02
HUT66755A (en) 1994-12-28
AU675798B2 (en) 1997-02-20
AU4488593A (en) 1994-03-03
EP0584876A3 (en) 1994-06-29
US5532150A (en) 1996-07-02
JPH06172201A (ja) 1994-06-21
US5661020A (en) 1997-08-26
HU9302440D0 (en) 1993-11-29
CA2101361A1 (en) 1994-02-28

Similar Documents

Publication Publication Date Title
MX9305082A (es) Sustancias proteinaceas biologicamente activas de oxido polialquilenico de bajo diol.
AR002280A1 (es) Un compuesto derivado del acido poli-pirrol-carboxamidonaftalenico, un procedimiento para su preparacion, una composicion farmaceutica que lo contieney un procedimiento para mejorar la biodisponibilidad sistemica de un compuesto biologicamente activo.
PT1161248E (pt) Composição farmacêutica que contém uma fonte de nitrato e um agente acidificante destinada ao tratamento de feridas abertas e queimaduras
GR3036792T3 (en) New bi- and tricyclic aminoalcohol esters, their preparation and their use in medicaments.
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
MX9206456A (es) Nuevos hibridos transformadores de los factores de crecimiento.
FI954986A (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
DE69905384T2 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
LV11818A (lv) Jauna farmaceitiska kompozicija stabilas pulverveida zalu formas pagatavosanai
ES8105991A1 (es) Un procedimiento para la preparacion de fenil-quinolicidinas
IT1240683B (it) Composizione farmaceutica contenente egf
ES8106498A1 (es) Un procedimiento para la preparacion de derivados del pirrol
NZ332497A (en) Pharmaceutical composition having a carrier system containing a combination of an alkylene glycol and unsaturated fatty acid alcohol as the solvent and a stiffening agent
FR2323393A1 (fr) Gel d'iodo-poloxamere
JPS5753492A (en) Novel propane diol derivative
DK176390D0 (da) Pyrazindiazohydroxidforbindelser
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
HU171537B (hu) Sposob poluchenija novykh slozhnykh efirov 5-n-butil-piridin-2-karbonovojj kisloty i kompozicijj soderzhahhikh ikh aktivnym agentom
EA013691B1 (ru) Композиция с высокой осмотической активностью антимикробного, противовоспалительного и регенерационного действия
ES2053414T1 (es) Complejos solubles de dextrano-glutation, metodo de preparacion y su uso.
FR2317936A1 (fr) Nouveaux derives de l'acide cis-epoxy-1,2 propylphosphonique et medicaments contenant notamment comme principes actifs des derives de l'acide cis-epoxy-1,2 propylphosphonique sous forme dextrogyre
CA803541A (en) Surfactant compositions from active hydrogen organic compounds, fatty acid esters and alkylene oxides, and related manufacturing process
CA2082495A1 (en) A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
CA910194A (en) Compositions containing physiologically active kawa compounds, process of making same, and method of using same in therapy
BG96407A (en) Medicaments for local treatment of wounds and inflammatory foci